Maravai LifeSciences Holdings, Inc. Class A Common Stock MRVI
$5.70
-1.38%
at last close
Analyst Consensus
- Consensus Rating
- Buy (1 Buy · 0 Hold · 0 Sell)
- Average Price Target
- $6.50
- Implied Upside
- +14.0%
- Price Target Range
- $6.50 – $6.50
- Analysts (12 mo)
- 1
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-07 | Wells FargoEvan Stampler |
Maintains | Overweight | $6 → $7 |
| 2026-05-08 | Wells FargoBrandon Couillard |
Maintains | Overweight | $5 → $6 |
| 2025-12-15 | Wells FargoBrandon Couillard |
Maintains | Overweight | $4 → $5 |
| 2025-08-12 | RBC CapitalConor McNamara |
Maintains | Outperform | $7 → $5 |
| 2025-05-13 | Craig-HallumChristian Schwab |
Maintains | Buy | $12 → $10 |
| 2025-05-13 | BairdCatherine Schulte |
Maintains | Neutral | $3 → $2 |
| 2025-03-25 | Morgan StanleyTejas Savant |
Maintains | Equal-weight | $7 → $5 |
| 2025-03-21 | UBSDan Brennan |
Maintains | Neutral | $8 → $3 |
| 2025-03-03 | B of A SecuritiesMichael Ryskin |
Maintains | Buy | $9 → $8 |
| 2025-02-26 | BairdCatherine Schulte |
Downgrades | Outperform → Neutral | $9 → $3 |
| 2024-12-05 | Goldman SachsMatthew Sykes |
Downgrades | Neutral → Sell | $7 → $4 |
| 2024-11-14 | Wolfe ResearchDoug Schenkel |
Initiates coverage on | Peer perform | — |
| 2024-11-08 | RBC CapitalConor McNamara |
Maintains | Outperform | $17 → $13 |
| 2024-11-08 | William BlairMatt Larew |
Downgrades | Outperform → Market perform | — |
| 2024-11-08 | BairdCatherine Schulte |
Maintains | Outperform | $10 → $9 |
| 2024-10-08 | Goldman SachsMatthew Sykes |
Maintains | Neutral | $8 → $7 |
| 2024-08-27 | Wells FargoBrandon Couillard |
Initiates coverage on | Overweight | $10 |
| 2024-08-16 | RBC CapitalConor McNamara |
Reiterates | Outperform | $15 |
| 2024-08-13 | Morgan StanleyTejas Savant |
Downgrades | Overweight → Equal-weight | $11 → $10 |
| 2024-08-08 | Goldman SachsMatthew Sykes |
Maintains | Neutral | $7 → $8 |
| 2024-08-08 | UBSDan Brennan |
Maintains | Neutral | $9 → $11 |
| 2024-07-09 | Goldman SachsMatthew Sykes |
Maintains | Neutral | $8 → $7 |
| 2024-05-09 | BairdCatherine Schulte |
Maintains | Outperform | $8 → $10 |
| 2024-04-10 | Craig-HallumChristian Schwab |
Initiates coverage on | Buy | $15 |
| 2024-02-23 | RBC CapitalConor McNamara |
Maintains | Outperform | $12 → $14 |
| 2024-02-23 | StifelDaniel Arias |
Maintains | Buy | $11 → $10 |
| 2023-12-12 | B of A SecuritiesMichael Ryskin |
Upgrades | Neutral → Buy | $10 → $8 |
| 2023-11-09 | Goldman SachsMatthew Sykes |
Maintains | Neutral | $8 → $7 |
| 2023-11-09 | Morgan StanleyTejas Savant |
Maintains | Overweight | $12 → $11 |
| 2023-08-09 | Morgan StanleyTejas Savant |
Maintains | Overweight | $27 → $12 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $5.70
- Market Cap
- $861.16 million
- 52-Week Range
- $1.99 – $7.44
- Average Volume
- 2.56 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.